Serum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndrome

Basit Öğe Kaydı
dc.contributor.authorKarakas, Mehmet Fatih
dc.contributor.authorBuyukkaya, Eyup
dc.contributor.authorKurt, Mustafa
dc.contributor.authorMotor, Sedat
dc.contributor.authorAkcay, Adnan Burak
dc.contributor.authorKarakas, Esra
dc.contributor.authorBuyukkaya, Sule
dc.date.accessioned2024-09-18T20:54:09Z
dc.date.available2024-09-18T20:54:09Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: The aim of the present study was to assess the association between the level of pentraxin-3 (PTX-3) and the severity of metabolic syndrome (MS). Subjects and Method: One hundred and two patients with MS and 101 consecutive age-and sex-matched control subjects were included in the study. The MS patients were classified into three groups based on the number of MS criteria, i.e. group 1: patients with 3 MS criteria, group 2: patients with 4 MS criteria, and group 3: patients with 5 MS criteria. Serum PTX-3 and high-sensitivity C-reactive protein (hs-CRP) levels were measured. Results: Group 1 had higher PTX-3 levels compared to the control group (0.58 +/- 0.11 ng/ml vs. 0.36 +/- 0.15 ng/ml, p < 0.001). PTX-3 levels were higher in group 3 than in both group 1 (0.90 +/- 0.06 ng/ml vs. 0.58 +/- 0.11 ng/ml, p < 0.001) and group 2 (0.90 +/- 0.06 ng/ml vs. 0.63 +/- 0.12 ng/ml, p < 0.001). Group 3, however, had higher hs-CRP levels than both group 1 (1.89 +/- 0.45 mg/dl vs. 1.40 +/- 0.44 mg/dl, p = 0.007) and group 2 (1.89 +/- 0.45 mg/dl vs. 1.47 +/- 0.58 mg/dl, p = 0.01). The control group had lower hs-CRP levels than group 1 (0.81 +/- 0.47 mg/dl vs. 1.40 +/- 0.44 mg/dl, p < 0.001) and group 2 (0.81 +/- 0.47 mg/dl vs. 1.47 +/- 0.58 mg/dl, p < 0.001). Serum PTX-3 levels correlated with serum hs-CRP levels (r = 0.49, p < 0.001). Conclusions: PTX-3, a novel inflammatory marker, was found to be associated with the severity of MS. Copyright (C) 2012 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000343904
dc.identifier.endpage279en_US
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue3en_US
dc.identifier.pmid23146973en_US
dc.identifier.scopus2-s2.0-84876050060en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage274en_US
dc.identifier.urihttps://doi.org/10.1159/000343904
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11623
dc.identifier.volume22en_US
dc.identifier.wosWOS:000317000100013en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofMedical Principles and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPentraxin-3en_US
dc.subjectMetabolic syndromeen_US
dc.subjectHigh-sensitivity C-reactive proteinen_US
dc.subjectInflammationen_US
dc.titleSerum Pentraxin-3 Levels Are Associated with the Severity of Metabolic Syndromeen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
128.13 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu